Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZS Associates

About this trial

This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The primary objective is to determine the validity of a self-assessment tool in encouraging undiagnosed participants, recruited through a social media campaign, to seek medical evaluation for suspected myasthenia gravis (MG).

Eligibility criteria

Qualifiers

Reside within the 50 states of the United States at the time of enrollment

Age 19 or older if reside in Nebraska or Alabama, Age 21 or older if reside in Mississippi, Age 18 years or older if reside in any other state

Active email account

Fluency in English (spoken / written), as demonstrated by the ability to read and sign the Informed Consent Form

Disqualifiers

Live in an overseas territory of the United States

Inability or unwillingness to provide written informed consent

Diagnosed myasthenia gravis, including sero-negative MG*

Diagnosed multiple sclerosis

Trial design

Treatments tested in this trial

  • Social media recruitment
  • Self-Assessment
  • Follow-up

Treatment groups

1,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

ZS Associates

Lead sponsor

UCB Pharma

Collaborator

University of California, San Francisco

Collaborator